Cytoluminescent Therapy

Cytoluminescent Therapy

Cytoluminescent Therapy, a proposed cancer treatment akin to Photodynamic Therapy (PDT), entails the use of a photosensitizer purportedly absorbed selectively by neoplastic and dysplastic tissue while being eliminated from normal tissue. Subsequently, the affected area is exposed to specific-wavelength light irradiation, activating the photosensitizer. The intended outcome is the targeted damage or eradication of tumor cells with minimal harm to normal tissues. However, clinical tests conducted up to 2003 involving 48 patients treated with this method did not demonstrate any positive effects.

The original providers of CLT in Killaloe, Ireland, have ceased offering the treatment. Much of their efficacy claims were based on anecdotal evidence rather than rigorous research. Notably, the wavelength of light utilized to activate the chlorophyll-derived photosensitizer in CLT lacks the ability to penetrate tissue beyond several millimeters. In contrast, FDA-approved PDT employs red light with a wavelength of approximately 600-700 nm, capable of penetrating human tissue up to 2 centimeters. It's crucial to note that no wavelength can fully penetrate the human body, contrary to assertions made by CLT proponents.